drugset
drugset / Trial / NCT03689010

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea

NCT03689010 ↗

Phase 1 Completed 1116 enrolled Sun Pharmaceutical Industries, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of moderate facial rosacea.

Timeline

Start
2017-12-12
Primary completion
2018-08-09
Completion
2018-09-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azelaic acid Small molecule 15 % Topical

Indications

rosacea